title: Effect of omega-3 fatty acid supplementation on platelet aggregability and platelet produced thromboxane.
abstract: We investigated the sustained effect of 12-week supplementation of 2.880 g/day of omega-3 fatty acids on platelet aggregability, platelet produced thromboxane B2 concentration and serum fatty acid composition in a double-blind controlled trial in 44 healthy mildly overweight eastern Finnish men recruited from a representative population sample. The supplementation was discontinued seven days before the biochemical measurements. Body weight, alcohol consumption and dietary composition remained constant during the study. Even though the percentage of eicosapentaenoic acid (20:5 omega 3) in total serum lipids increased by 37% (p less than 0.01) and that of dihomo-gamma-linolenic acid (20:3 omega 6) decreased by 18% (p less than 0.01) more in the omega-3 supplemented than placebo group during supplementation, there were no significant differences in the changes in either the ADP induced platelet aggregation or in vitro platelet produced thromboxane B2 concentration between the groups. These data suggest that omega-3 fatty acids have no detectable sustained effect either on ADP induced platelet aggregation or on thromboxane produced by the platelets in vitro.
authors: Kuopio Research Institute of Exercise Medicine, Finland.
authors: R
authors: R
authors: Salonen
authors: T
authors: T
authors: Nikkari
authors: K
authors: K
authors: Seppänen
authors: J M
authors: JM
authors: Venäläinen
authors: M
authors: M
authors: Ihanainen
authors: V
authors: V
authors: Rissanen
authors: R
authors: R
authors: Rauramaa
authors: J T
authors: JT
authors: Salonen
mesh_terms: D000328:Adult; D001792:Blood Platelets / Q000378:metabolism*; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage / Q000494:pharmacology*; D004281:Docosahexaenoic Acids; D004311:Double-Blind Method; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage / Q000494:pharmacology*; D005387:Finland; D005395:Fish Oils / Q000008:administration & dosage; D006801:Humans; D019787:Linoleic Acid; D008041:Linoleic Acids / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D000069463:Olive Oil; D010938:Plant Oils / Q000008:administration & dosage; D010974:Platelet Aggregation / Q000187:drug effects; D013929:Thromboxane B2 / Q000096:biosynthesis*
chemical_list: D004042:Dietary Fats, Unsaturated; D004338:Drug Combinations; D005231:Fatty Acids, Unsaturated; D005395:Fish Oils; D008041:Linoleic Acids; C045153:Maxepa; D000069463:Olive Oil; D010938:Plant Oils; D004281:Docosahexaenoic Acids; D013929:Thromboxane B2; D019787:Linoleic Acid; D015118:Eicosapentaenoic Acid